- Investor's Business Daily•3 days ago
Amgen will likely triumph in a patent battle with Regeneron and Sanofi, Leerink says.
- TheStreet.com•4 days ago
The stock has taken a beating, but users of Afrezza are loyal to the drug.
- Financial Times•4 days ago
Under pressure to deliver a new blockbuster medicine, Sanofi, France's biggest drugmaker, bet big on a new class of cholesterol-lowering products with its Praluent treatment. Last week it was dealt a harsh ...
SAN.PA : Summary for SANOFI - Yahoo Finance
Paris - Paris Delayed Price. Currency in EUR
Add to watchlist
|Bid||71.12 x 1000|
|Ask||71.74 x 44000|
|Day's Range||77.36 - 78.16|
|52 Week Range||62.50 - 79.07|
|PE Ratio (TTM)||23.75|
|Dividend & Yield||3.35 (4.05%)|
|1y Target Est||N/A|